University Polyclinic Hospital of Modena
Welcome,         Profile    Billing    Logout  
 5 Trials 
37 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lang, David M
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Recruiting
2
360
Europe, Canada, US, RoW
Buloxibutid, C21, Placebo
Vicore Pharma AB, Population Services International
Idiopathic Pulmonary Fibrosis (IPF)
05/27
06/27
Mussini, Cristina
PETERPEN, NCT03671967: PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae

Recruiting
4
1084
Canada, RoW
Piperacillin/tazobactam, Meropenem
Rambam Health Care Campus, Rabin Medical Center, University of Modena and Reggio Emilia, Tel Aviv Medical Center, Meir Medical Center, Soroka University Medical Center, The Chaim Sheba Medical Center, McGill University Health Centre/Research Institute of the McGill University Health Centre, Jewish General Hospital, Canadian Institutes of Health Research (CIHR), Hadassah Medical Organization
Beta Lactam Resistant Bacterial Infection, Enterobacteriaceae Infections, Bacteremia
01/27
04/27
EDOLAS, NCT04979468: Early DOlutegravir/LAmivudine Switching After Virological Suppression ( Study)

Recruiting
3
440
Europe
DOVATO, dolutegravir/lamivudine
Societa' Italiana Di Malattie Infettive E Tropicali
HIV-1-infection
04/23
04/24
MARIO, NCT05178862 / 2022-000648-32: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Terminated
3
68
Europe, Canada, US, RoW
SCY-078, Ibrexafungerp, Fluconazole, Diflucan, Echinocandin, Caspofungin, Micafungin, Anidulafungin
Scynexis, Inc., SCYNEXIS, Inc.
Candidiasis, Invasive, Candidemia
11/25
12/25
OASIS, NCT05101187 / 2024-513030-38-00 / 2021-000386-32: Olorofim Aspergillus Infection Study

Active, not recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive fungal infections due to Aspergillus spp.
11/25
11/26
NCT06061081 / 2023-505780-37-00: A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1

Terminated
2
21
Europe, US, RoW
VH3739937, Placebo
ViiV Healthcare, GSK Pharma R&D
HIV Infections
08/24
08/24
IRENE, NCT03339063: The Italian REgistry of Pulmonary Non-tuberculous mycobactEria

Recruiting
N/A
500
Europe
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Niguarda Hospital, Azienda Ospedaliera San Gerardo di Monza, ASST Fatebenefratelli Sacco, Fondazione IRCCS Policlinico San Matteo di Pavia, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Turin, Italy, A.O.U. Città della Salute e della Scienza - Molinette Hospital, Azienda Unità Locale Socio Sanitaria n.9 Treviso, Ospedale Maggiore Di Trieste, Azienda Ospedaliero-Universitaria di Modena, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Università degli Studi di Ferrara, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Azienda Ospedaliero, Universitaria Pisana, Azienda Ospedaliero-Universitaria Careggi, Ospedale San Jacopo, Pistoia, Italy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Azienda Policlinico Umberto I, Istituto Nazionale per le Malattie Infettive Spallanzani, Roma, Policlinico Universitario, Catania, Azienda Ospedaliera Universitaria Policlinico "G. Martino", Azienda Ospedaliera Cosenza, Azienda Ospedaliero Universitaria di Sassari
Nontuberculous Mycobacteria
12/22
12/22
NCT04090151: The RESPOND Outcomes Study

Recruiting
N/A
37853
Europe, RoW
Rigshospitalet, Denmark, Gilead Sciences, ViiV Healthcare
HIV
12/25
12/25
Rotstein, Coleman
MARIO, NCT05178862 / 2022-000648-32: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Terminated
3
68
Europe, Canada, US, RoW
SCY-078, Ibrexafungerp, Fluconazole, Diflucan, Echinocandin, Caspofungin, Micafungin, Anidulafungin
Scynexis, Inc., SCYNEXIS, Inc.
Candidiasis, Invasive, Candidemia
11/25
12/25
Rogliani, Paola
ENDURA-2, NCT06961214 / 2024-520417-41-00: Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

Recruiting
3
960
Europe, US, RoW
Depemokimab, GSK3511294, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Pulmonary Disease, Chronic Obstructive
08/29
08/29
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Recruiting
2
360
Europe, Canada, US, RoW
Buloxibutid, C21, Placebo
Vicore Pharma AB, Population Services International
Idiopathic Pulmonary Fibrosis (IPF)
05/27
06/27
NCT02632123: Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis

Completed
N/A
260
Europe, Canada
London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's, Western University, Canada, Università degli studi di Roma Tor Vergata, University of Waterloo
Idiopathic Pulmonary Fibrosis
06/24
06/24
Bondue, Benjamin
IMPALA-2, NCT04544293 / 2020-001263-85: Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Active, not recruiting
3
164
Europe, Canada, Japan, US, RoW
Molgramostim, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF), Placebo, Placebo nebulizer, Molgramostim Open-label
Savara Inc., Savara ApS,
Autoimmune Pulmonary Alveolar Proteinosis
11/23
05/27
TETON-2, NCT05255991 / 2024-514761-19-00 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Completed
3
597
Europe, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics, UNITED THERAPEUTICS CORPORATION
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
TETON-PPF, NCT05943535 / 2023-504904-26-00: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis

Recruiting
3
698
Europe, Canada, US, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
11/27
11/27
FAPIPET, NCT06189820: Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases

Recruiting
2
70
Europe
FAPI PET/CT
Erasme University Hospital
Pulmonary Fibrosis, Lung Fibrosis, Idiopathic Pulmonary Fibrosis, FAP
03/27
03/27
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Recruiting
2
360
Europe, Canada, US, RoW
Buloxibutid, C21, Placebo
Vicore Pharma AB, Population Services International
Idiopathic Pulmonary Fibrosis (IPF)
05/27
06/27
Dahlqvist, Caroline
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

Recruiting
3
440
Europe, Canada, Japan, US, RoW
Belimumab, BENLYSTA, GSK1550188, Placebo
GlaxoSmithKline
Lung Diseases, Interstitial
10/28
12/28
TETON-2, NCT05255991 / 2024-514761-19-00 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Completed
3
597
Europe, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics, UNITED THERAPEUTICS CORPORATION
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Recruiting
2
360
Europe, Canada, US, RoW
Buloxibutid, C21, Placebo
Vicore Pharma AB, Population Services International
Idiopathic Pulmonary Fibrosis (IPF)
05/27
06/27
Schwedler, Katrin
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Recruiting
2
360
Europe, Canada, US, RoW
Buloxibutid, C21, Placebo
Vicore Pharma AB, Population Services International
Idiopathic Pulmonary Fibrosis (IPF)
05/27
06/27
NCT03318406: Post-Market BTVA Registry

Recruiting
N/A
300
Europe
Bronchoscopic Thermal Vapor Ablation, BTVA, InterVapor
Uptake Medical Technology, Inc.
Emphysema or COPD
12/27
12/30
Arabadzhiev, Georgi
MARIO, NCT05178862 / 2022-000648-32: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Terminated
3
68
Europe, Canada, US, RoW
SCY-078, Ibrexafungerp, Fluconazole, Diflucan, Echinocandin, Caspofungin, Micafungin, Anidulafungin
Scynexis, Inc., SCYNEXIS, Inc.
Candidiasis, Invasive, Candidemia
11/25
12/25
Nardini, Giulia
MARIO, NCT05178862 / 2022-000648-32: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Terminated
3
68
Europe, Canada, US, RoW
SCY-078, Ibrexafungerp, Fluconazole, Diflucan, Echinocandin, Caspofungin, Micafungin, Anidulafungin
Scynexis, Inc., SCYNEXIS, Inc.
Candidiasis, Invasive, Candidemia
11/25
12/25
Patyk, Iwona
BBT877-IPF-004, NCT05483907: To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF

Hourglass Jul 2023 - Dec 2023 : Interim data for the treatment of IPF
Checkmark Initiation of trial in idiopathic pulmonary fibrosis
Nov 2022 - Nov 2022: Initiation of trial in idiopathic pulmonary fibrosis
Completed
2
129
Europe, US, RoW
BBT-877, Placebo
Bridge Biotherapeutics, Inc.
Idiopathic Pulmonary Fibrosis
01/25
02/25
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Recruiting
2
360
Europe, Canada, US, RoW
Buloxibutid, C21, Placebo
Vicore Pharma AB, Population Services International
Idiopathic Pulmonary Fibrosis (IPF)
05/27
06/27
Gauthier, Patrice
NCT06372496: Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

Active, not recruiting
4
1366
Canada, Japan, US, RoW
Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists
GlaxoSmithKline
Asthma
07/25
03/27
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

Recruiting
3
440
Europe, Canada, Japan, US, RoW
Belimumab, BENLYSTA, GSK1550188, Placebo
GlaxoSmithKline
Lung Diseases, Interstitial
10/28
12/28
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Recruiting
2
360
Europe, Canada, US, RoW
Buloxibutid, C21, Placebo
Vicore Pharma AB, Population Services International
Idiopathic Pulmonary Fibrosis (IPF)
05/27
06/27
Breyer, Marie-Kathrin
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Recruiting
2
360
Europe, Canada, US, RoW
Buloxibutid, C21, Placebo
Vicore Pharma AB, Population Services International
Idiopathic Pulmonary Fibrosis (IPF)
05/27
06/27
NCT01727518: The Austrian LEAD (Lung hEart sociAl boDy) Study

Active, not recruiting
N/A
14966
Europe
As the LEAD study is an observational cohort study, there is no intervention to report.
Ludwig Boltzmann Institute for Lung Health
Respiration Disorders, Body Composition, Beneficial, Metabolic Health
10/16
10/28
NCT06522347: Mycobacteria Registry Study: Prospective Observational Study in Austria

Recruiting
N/A
1000
Europe
Ludwig Boltzmann Institute for Lung Health, Sigmund Freud PrivatUniversitat
Non-Tuberculous Mycobacterial Pneumonia, Tuberculosis
12/53
12/53
NCT06522334: Interstitial Lung Disease Registry Study: Prospective and Retrospective Observational Study in Austria

Recruiting
N/A
400
Europe
Ludwig Boltzmann Institute for Lung Health
Interstitial Lung Disease
02/34
02/34
Glaeser, Sven
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Recruiting
2
360
Europe, Canada, US, RoW
Buloxibutid, C21, Placebo
Vicore Pharma AB, Population Services International
Idiopathic Pulmonary Fibrosis (IPF)
05/27
06/27
Tomos, Ioannis
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Recruiting
2
360
Europe, Canada, US, RoW
Buloxibutid, C21, Placebo
Vicore Pharma AB, Population Services International
Idiopathic Pulmonary Fibrosis (IPF)
05/27
06/27
Viehrig, Maren
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Recruiting
2
360
Europe, Canada, US, RoW
Buloxibutid, C21, Placebo
Vicore Pharma AB, Population Services International
Idiopathic Pulmonary Fibrosis (IPF)
05/27
06/27
Manali, Efrosyni
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Recruiting
2
360
Europe, Canada, US, RoW
Buloxibutid, C21, Placebo
Vicore Pharma AB, Population Services International
Idiopathic Pulmonary Fibrosis (IPF)
05/27
06/27

Download Options